CopyCat

Based in San Francisco, California, CopyCat develops an artificial intelligence platform that automates biopsy callbacks and routine patient outreach for specialized dermatology clinics. The software integrates directly with electronic health record systems such as EMA and EzDerm to identify patients requiring follow-up care, communicate medical results via phone, text, or email, and log outcomes back into clinical workflows. Operating with a lean team of two to three employees, the company provides a HIPAA-compliant solution that also manages broader administrative tasks including patient scheduling, insurance verification, and inbound fax triage. The enterprise functions as a software-as-a-service business and recently participated in the Winter 2025 batch of its lead investor, securing early-stage venture capital backing from institutional funds including Y Combinator and Flex Capital. CopyCat was officially founded in 2024 by Abhi Balijepalli, Graham Sabin, and Zyad Elgohary.

High-Level Overview

CopyCat is an AI-powered biopsy callback platform designed specifically for dermatology clinics. It automates the delivery of lab results to patients using voice AI, providing simple explanations, answering FAQs, and scheduling follow-up appointments. This reduces administrative burdens on dermatologists and enhances patient engagement by ensuring timely and clear communication of biopsy outcomes. The platform integrates seamlessly with existing electronic health records (EHR) and clinic workflows, aiming to improve operational efficiency and patient retention in dermatology practices.

For an investment firm, CopyCat represents a cutting-edge solution in the intersection of AI, healthcare automation, and dermatology, addressing a critical bottleneck in patient communication and follow-up care. Its mission centers on transforming dermatology clinics by automating repetitive administrative tasks, reducing overhead costs, and enabling providers to focus on patient care. The investment philosophy would likely emphasize AI-driven healthcare innovation, workflow automation, and patient-centric digital health solutions. Key sectors include AI in healthcare, dermatology, and clinical workflow automation. CopyCat’s impact on the startup ecosystem lies in advancing AI adoption in specialty medical practices and demonstrating scalable automation in clinical settings.

Origin Story

CopyCat was founded by Abhi, Graham, and Zyad, a team combining engineering expertise and dermatology domain knowledge. The idea emerged from firsthand experience with the inefficiencies and administrative burdens in dermatology clinics, particularly around managing biopsy results and patient callbacks. Early traction was gained by embedding on-site with clinic staff to observe workflows, identifying automation opportunities, and delivering tailored AI solutions that fit real-world clinical processes. This hands-on approach helped build trust and demonstrated immediate value, accelerating adoption.

Core Differentiators

• Product Differentiators: CopyCat uses advanced voice AI to automate patient callbacks, providing clear explanations and handling FAQs, which is unique compared to traditional manual or text-based communication methods.
• Developer Experience: The platform offers a self-serve model with private onboarding support, enabling clinics to integrate AI without complex IT overhead.
• Speed and Ease of Use: No virtual machines or desktop installs are required, minimizing maintenance and deployment challenges.
• Community Ecosystem: CopyCat fosters a collaborative environment through private Slack channels for onboarding and best practice sharing among users, enhancing user engagement and support.

Role in the Broader Tech Landscape

CopyCat rides the growing trend of AI and automation in healthcare, particularly in dermatology where early detection and patient follow-up are critical. The timing is favorable due to increasing demand for efficient patient communication, rising biopsy volumes, and the need to reduce clinician administrative burdens. Market forces such as the expansion of telehealth, AI-driven diagnostics, and digital patient engagement tools support CopyCat’s growth. By automating callbacks and explanations, CopyCat influences the broader ecosystem by improving patient adherence to care plans, reducing no-shows, and enabling dermatologists to focus on clinical tasks rather than administrative workflows.

Quick Take & Future Outlook

Looking ahead, CopyCat is poised to expand its AI capabilities beyond callbacks to include broader clinical workflow automation such as triage, documentation, and prescribing support. Trends shaping its journey include the increasing integration of AI in specialty care, regulatory acceptance of AI tools in clinical settings, and growing patient expectations for digital engagement. As CopyCat scales, it may influence the dermatology sector by setting new standards for AI-driven patient communication and operational efficiency, potentially expanding into other specialties facing similar administrative challenges. This evolution ties back to its core mission of transforming dermatology clinics into more efficient, patient-centered practices through AI innovation.